Phathom Pharmaceuticals (PHAT) Receivables (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Receivables for 4 consecutive years, with $97.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Receivables rose 90.07% year-over-year to $97.4 million; the TTM figure through Jun 2026 stood at $97.4 million (up 90.07% YoY), while the FY2025 annual figure was $78.1 million, up 101.38% from the prior year.
• Receivables grew to $97.4 million in Q2 2026 per PHAT's latest filing, from $80.7 million in the prior quarter.
• Across five years, Receivables topped out at $97.4 million in Q2 2026 and bottomed at $1.3 million in Q4 2023.
• Historically, Receivables has averaged $43.1 million across 4 years, with a median of $38.8 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables jumped 2875.23% — and 2026, when it surged 90.07%.
• Phathom Pharmaceuticals' Receivables stood at $1.3 million in 2023, then surged by 2875.23% to $38.8 million in 2024, then soared by 96.17% to $76.1 million in 2025, then rose by 28.0% to $97.4 million in 2026.
• Business Quant data shows PHAT's Receivables at $97.4 million in Q2 2026, $80.7 million in Q1 2026, and $76.1 million in Q4 2025.